Observational Study of Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis
Authors:
- Ariane L. HerrickAriane L. Herrick
- Mark LuntMark Lunt
- Nina WhidbyNWNina Whidby
- Holly EnnisHolly Ennis
- Alan SilmanASAlan Silman
- NEIL McHUGHNMNEIL McHUGH
- Christopher P. DentonCDChristopher P. Denton
- 1 December 2009
- journal article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 37 (1) , 116-124
Abstract
Objective. Randomized clinical trials in early diffuse cutaneous systemic sclerosis (dcSSc) are challenging. We used an observational approach to estimate the relative effectiveness of different current treatment approaches, capturing entry and outcome data in a standardized way.Keywords
This publication has 24 references indexed in Scilit:
- Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo‐controlled phase I/II trial of CAT‐192Arthritis & Rheumatism, 2007
- A multicenter, prospective, randomized, double‐blind, placebo‐controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in sclerodermaArthritis & Rheumatism, 2006
- Cyclophosphamide versus Placebo in Scleroderma Lung DiseaseNew England Journal of Medicine, 2006
- Systemic sclerosis: hypothesis-driven treatment strategiesThe Lancet, 2006
- Scleroderma—clinical and pathological advancesBest Practice & Research Clinical Rheumatology, 2004
- Following the Molecular Pathways toward an Understanding of the Pathogenesis of Systemic SclerosisAnnals of Internal Medicine, 2004
- A randomized, controlled trial of methotrexate versus placebo in early diffuse sclerodermaArthritis & Rheumatism, 2001
- Scleroderma and related disorders: therapeutic aspectsBest Practice & Research Clinical Rheumatology, 2000
- High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trialArthritis & Rheumatism, 1999
- Interferon-? does not improve outcome at one year in patients with diffuse cutaneous scleroderma: Results of a randomized, double-blind, placebo-controlled trialArthritis & Rheumatism, 1999